Pursue life without cancer
Genetic analysis in hematooncology

The WT1 mRNA OneStep Assay is a highly sensitive real-time PCR assay. It enables quantitation of Wilms’ tumour-1 gene (WT1) mRNA expression in RNA extracted from peripheral blood leukocytes or nucleated cells in bone marrow. The assay is intended to aid in the minimal residual disease monitoring with acute myeloid leukemia (AML), diagnosis and progression monitoring of patients with myelodysplastic syndrome (MDS). Validated using the Applied Biosystems™ 7500 Dx qPCR platform for clinical performance you can trust, all within a simplified workflow.

Request a quote  Download flyer

The WT1 mRNA OneStep Assay kit benefits:

  • Highly sensitive and reproducible WT1 mRNA quantitation
  • Proven performance using RNA from either peripheral blood or bone marrow
  • A simplified one-step qRT-PCR workflow with reduced hands-on time compared to two-step qRT-PCR assays
  • Control primers included to enable accurate and consistent quantitation
  • CE-IVD registration—for In Vitro Diagnostic Use in the European Union

(1) Sugiyama H (2001) Wilms' tumor gene WT1: its oncogenic function and clinical application. Int J Hematol 73(2):177–187.
(2) Liu-Yin J et al. (2012) Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial. Blood 120:2826-2835.
(3) Inoue K et al. (1994) WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 84(9):3071–3079.
(4) Rosenfeld C, Cheever MA, Gaiger A et al. (2003) WT1 in acute leukemia, chronic myelogenous leukemia and myelodysplastic syndrome: therapeutic potential of WT1 targeted therapies. Leukemia (17):1301–1312.
(5) Inoue K et al. (1996) Long-term follow-up of minimal residual disease in leukemia patients by monitoring WT1 (Wilms tumor gene) expression levels. Blood 88 (6):2267–2278.
(6) Locatelli F, Zecca M, Pession A et al. (1995) Myelodysplastic syndromes: the pediatric point of view. Haematologica 80:268–279.
(7) Ueda Y et al. (2013) Clinical evaluation of WT1 mRNA expression levels in peripheral blood and bone marrow in patients with myelodysplastic syndromes. Leuk Lymphoma 54(7):1450–1458.

For In Vitro Diagnostic Use in the European Union.
Available in: Austria, Belgium, France, Finland, Germany, Iceland, Ireland, Italy, Luxembourg, Malta, Netherlands, Poland, Slovenia, Spain, Switzerland, and United Kingdom.